Education
About Us
Working with TipRanks
Follow Us
Laboratorios Farmaceuticos Rovi, SA (GB:0ILL)
LSE:0ILL
Total Valuation
Laboratorios Farmaceuticos Rovi has a market cap or net worth of €4.29B. The enterprise value is €4.38B.
Market Cap€4.29B
Enterprise Value€4.38B
Share Statistics
Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,235,764
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 16.21%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.15
Return on Invested Capital (ROIC)16.21%
Return on Capital Employed (ROCE)0.22
Revenue Per Employee338.41K
Profits Per Employee63.92K
Employee Count2,197
Asset Turnover0.78
Inventory Turnover1.01
Valuation Ratios
The current PE Ratio of Laboratorios Farmaceuticos Rovi is 30.8. Laboratorios Farmaceuticos Rovi’s PEG ratio is 7.72.
PE Ratio30.8
PS Ratio4.37
PB Ratio4.89
Price to Fair Value4.89
Price to FCF27.03
Price to Operating Cash Flow23.21
PEG Ratio7.72
Income Statement
In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 743.48M and earned 140.44M in profits. Earnings per share was 2.75.
Revenue743.48M
Gross Profit451.65M
Operating Income173.14M
Pretax Income183.26M
Net Income140.44M
EBITDA203.52M
Earnings Per Share (EPS)2.75
Cash Flow
In the last 12 months, operating cash flow was 186.77M and capital expenditures -66.52M, giving a free cash flow of 120.25M billion.
Operating Cash Flow186.77M
Free Cash Flow120.25M
Free Cash Flow per Share2.35
Dividends & Yields
Laboratorios Farmaceuticos Rovi pays an annual dividend of €0.757, resulting in a dividend yield of 1.21%
Dividend Per Share€0.757
Dividend Yield1.21%
Payout Ratio31.99%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change61.12%
50-Day Moving Average70.98
200-Day Moving Average60.52
Relative Strength Index (RSI)80.47
Average Volume (3m)17.17K
Important Dates
Laboratorios Farmaceuticos Rovi upcoming earnings date is May 13, 2026, TBA (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 21.99%
Current Ratio3.14
Quick Ratio1.55
Debt to Market Cap0.04
Net Debt to EBITDA0.24
Interest Coverage Ratio60.84
Taxes
In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 42.90M in taxes.
Income Tax42.90M
Effective Tax Rate0.23
Enterprise Valuation
Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 16.19, with an EV/FCF ratio of 27.43.
EV to Sales4.43
EV to EBITDA16.19
EV to Free Cash Flow27.43
EV to Operating Cash Flow17.78
Balance Sheet
Laboratorios Farmaceuticos Rovi has €97.98M in cash and marketable securities with €146.09M in debt, giving a net cash position of -€48.11M billion.
Cash & Marketable Securities€97.98M
Total Debt€146.09M
Net Cash-€48.11M
Net Cash Per Share-€0.94
Tangible Book Value Per Share€12.57
Margins
Gross margin is 63.79%, with operating margin of 23.29%, and net profit margin of 18.89%.
Gross Margin63.79%
Operating Margin23.29%
Pretax Margin24.65%
Net Profit Margin18.89%
EBITDA Margin27.37%
EBIT Margin23.29%
Analyst Forecast
The average price target for Laboratorios Farmaceuticos Rovi is €90.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€90.00
Price Target Upside50.50% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―